Amgen Fails At US Patent Board In Humira Challenge
This article was originally published in Scrip
Executive Summary
Amgen Inc. failed to convince the US Patent & Trademark Office (US PTO) Patent Trial and Appeal Board (PTAB) to institute trials under so-called inter partes reviews (IPRs) in the company's challenge of two patents, known as '157 and '158, held by AbbVie Inc. on its tumor necrosis factor blocker Humira (adalimumab).